Nicole Meisner-Kober is a Biomedical Researcher dedicated to developing innovative therapies from basic discovery to clinical translation and industrial realisation, with a focus on RNA and extracellular vesicle biology.

Nicole has a background in Molecular Biology and Biophysical Chemistry and over 22 years of research and leadership experience both in academia and the global pharmaceutical industry. She has a strong track record of developing partnerships and research structures for private-public partnerships and bridging between the academic, clinical and industry sectors, with 360° integration of stakeholders from relevant groups ranging from scientists, patients, clinicians, drug developers, funding bodies and policy makers to the public. As an internationally established scientist in her field, she is engaged in scientific advisory boards, scientific award juries, consultant for biotech and pharma companies and as a scientific expert evaluator for major private and public funding agencies, including the European Union.

From 2005 to 2018, her team at the Novartis Institutes for Biomedical Research operating at sites in Vienna, Basel, and Cambridge US, has made seminal contributions to the development of RNA drugs and RNA delivery technologies including Lipid Nanoparticles and bioinspired delivery vehicles, as well as drug discovery for neurodegenerative RNA repeat expansion diseases and other RNA pathologies. Her research has further contributed fundamental discoveries on the molecular mechanisms of posttranscriptional RNA regulation as well as RNA and EV trafficking biology. Since 2018, Nicole is Professor of Chemical Biology and Biological Therapeutics at the Paris-Lodron University Salzburg (PLUS) where she has been actively engaged in forming close alliances with partners from the Paracelsus Medical University Salzburg (PMU) and the Salzburg University Hospital (SALK) to establish a new hub in Salzburg for discovery, development, manufacturing, and translation of Nanovesicular therapies from basic research into applications. Since 2024, she is director of the newly founded Ludwig Boltzmann Institute of Nanovesicular Precision Medicine in Salzburg, Austria.